Drugs / Deleobuvir
Deleobuvir
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT01983566 | Nov 2013 → Jan 2014 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT01941615 | Nov 2013 → Jan 2014 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT01965431 | Oct 2013 → Jan 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01957657 | Oct → Dec 2013 | impaired renal function disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT01737996 | Nov 2012 → Mar 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01605461 | May → Jun 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01525628 | Apr 2012 → Dec 2013 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01347086 | May → Jun 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02182401 | Jul → Aug 2009 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02182414 | May → Sep 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00905632 | May 2009 → Mar 2011 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02176525 | Dec 2007 → Dec 2009 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02182388 | Jan → May 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01830127 | Apr 2013 → Oct 2014 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01528735 | Feb 2012 → Aug 2013 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01132313 | May 2010 → Oct 2014 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01858961 | May 2013 → Jul 2016 | chronic hepatitis C virus infection | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 3 | NCT01732796 | Dec 2012 → Jan 2015 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01728324 | Nov 2012 → Feb 2014 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01535638 Comparator | Feb → Mar 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01859962 Comparator | May 2013 → May 2014 | chronic hepatitis C virus infection | Presidio Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | deleobuvir | “HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.” PMID 27920566 ↗ Nov 20163“Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection.” PMID 23558093 ↗ Apr 2013 “faldaprevir with deleobuvir (BI 207127) and ribavirin” PMID 27920566 ↗ Nov 2016 “BI 207127 (Deleobuvir)” NCT01965431 ↗ |
| Known as | BI 207127 | “Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection.” PMID 23558093 ↗ Apr 201316“faldaprevir with deleobuvir (BI 207127) and ribavirin” PMID 27920566 ↗ Nov 2016 |
| Known as | BI 207127 NA | “Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA” NCT01605461 ↗ |
| Known as | BI-207127 SODIUM SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL2403318 ↗ |
| Known as | DELEOBUVIR SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2403318 ↗ |
| Action | Inhibit | “BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.” PMID 22414766 ↗ Mar 2012 |
| Modality | Small molecule | “BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.” PMID 22414766 ↗ Mar 2012 |
| Route | Oral | “Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1” PMID 23558093 ↗ Apr 2013 |